FIRST AMENDMENT TO THE CD71 CO-DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (the “Amendment”) to the CD7l Co-Development and License Agreement dated April 21, 2016 (the “Agreement”) by and between CytomX Therapeutics, Inc., a corporation organized under the laws of Delaware (“Licensor”) and AbbVie Ireland Unlimited Company, an unlimited company organized under the laws of Ireland (“AbbVie”) is effective as of October 5, 2016. Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to Research Collaboration Agreement (the “Second Amendment”) is made effective as of the date of the last signature below by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business being 830 Winter Street, Waltham, Massachusetts 02451, USA, and CytomX Therapeutics, Inc., a Delaware corporation (“CytomX”), with its principal place of business being 343 Oyster Point Blvd., Suite 100, South San Francisco, California 94080. ImmunoGen and CytomX are herein sometimes referred to as a “Party” and collectively as the “Parties.”
THIRD AMENDMENT TO THE CD71 CO-DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment (the “Amendment”) to the CD71 Co-Development and License Agreement dated April 21, 2016, as amended (the “Agreement”) by and between CytomX Therapeutics, Inc., a corporation organized under the laws of Delaware (“Licensor”) and AbbVie Ireland Unlimited Company, an unlimited company organized under the laws of Ireland (“AbbVie” ) is effective as of January 3, 2018. Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
THIRD AMENDMENT TO RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment to Research Collaboration Agreement (the “Third Amendment”) is made effective as of the date of the last signature below by and between ImmunoGen, Inc., a Massachusetts corporation (“lmmunoGen”), with its principal place of business being 830 Winter Street, Waltham, Massachusetts 02451-1477, and CytomX Therapeutics, Inc., a Delaware corporation (“CytomX”), with its principal place of business being 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080. ImmunoGen and CytomX are herein sometimes referred to as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENT BETWEEN CYTOMX THERAPEUTICS, INC. AND IMMUNOGEN, INC. FEBRUARY 12, 2016License Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”) is entered into as of February 12, 2016 (the “Effective Date”), by and between CytomX Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 343 Oyster Point Blvd., Suite 100, South San Francisco, California, 94080 United States (“CytomX”) and ImmunoGen, Inc., a corporation organized and existing under the laws of Massachusetts and having a place of business at 830 Winter Street, Waltham, Massachusetts, 02451 (“ImmunoGen”). CytomX and ImmunoGen may each be referred to herein individually as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO THE CD71 CO-DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 6th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment (the “Amendment”) to the CD71 Co-Development and License Agreement dated April 21, 2016, as amended (the “Agreement”) by and between CytomX Therapeutics, Inc., a corporation organized under the laws of Delaware (“Licensor”) and AbbVie Ireland Unlimited Company, an unlimited company organized under the laws of Ireland (“AbbVie”) is effective as of March 31, 2017. Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
